O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. (2nd July 2019) - Pietrantonio, F; Lobefaro, R; Antista, M; Miceli, R; Raimondi, A; Lonardi, S; Rimassa, L; Saggio, S; Capone, I; Farina, G; Longarini, R; Mosconi, S; et al.